Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | FPR3 | P25089 | 7/20 | 0.50 |
| ▸ | FPR2 | P25090 | 7/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.49 |
| ▸ | WNT1 | P04628 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20270816 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2CCNE1CDK2FPR3FPR2 | |
| SCHEMBL10226337 | 0.82 | MKNK1 (0.62) | MKNK1SMN1; SMN2CCNE2CCNE1CDK2 | |
| SCHEMBL17631691 | 0.79 | PTPN2 (0.51) | MKNK1FPR3FPR2RAB9ANPC1 | |
| SCHEMBL25273658 | 0.77 | MKNK1 (0.60) | MKNK1SMN1; SMN2CCNE2CCNE1CDK2 | |
| SCHEMBL31272043 | 0.77 | MKNK1 (0.66) | MKNK1SMN1; SMN2CCNE2CCNE1CDK2 | |
| SCHEMBL25606129 | 0.75 | MKNK1 (0.77) | MKNK1SMN1; SMN2CCNE2CCNE1CDK2 | |
| SCHEMBL25609256 | 0.75 | MKNK1 (0.81) | MKNK1CCNE2CCNE1CDK2GSK3B | |
| SCHEMBL25219590 | 0.74 | MKNK1 (0.76) | MKNK1SMN1; SMN2CCNE2CCNE1CDK2 | |
| SCHEMBL25217762 | 0.74 | NPC1 (0.64) | MKNK1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL31271851 | 0.74 | SMN1; SMN2 (0.46) | SMN1; SMN2CCNE1CDK2FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | MKNK1 105/4885SMN1; SMN2 551/4885CCNE2 2282/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | MKNK1 162/4885SMN1; SMN2 157/4885CCNE2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.